1. Home
  2. HOV vs NGNE Comparison

HOV vs NGNE Comparison

Compare HOV & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hovnanian Enterprises Inc.

HOV

Hovnanian Enterprises Inc.

HOLD

Current Price

$119.16

Market Cap

726.0M

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$33.67

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOV
NGNE
Founded
1959
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
726.0M
744.9M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
HOV
NGNE
Price
$119.16
$33.67
Analyst Decision
Sell
Strong Buy
Analyst Count
2
7
Target Price
$97.00
$63.57
AVG Volume (30 Days)
102.8K
194.2K
Earning Date
05-19-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.93
EPS
1.55
N/A
Revenue
$2,978,581,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.96
N/A
P/E Ratio
$74.79
N/A
Revenue Growth
N/A
N/A
52 Week Low
$91.52
$15.93
52 Week High
$162.06
$43.66

Technical Indicators

Market Signals
Indicator
HOV
NGNE
Relative Strength Index (RSI) 43.10 43.71
Support Level $107.68 $31.20
Resistance Level $127.03 $42.84
Average True Range (ATR) 4.05 2.43
MACD -0.76 -0.42
Stochastic Oscillator 28.51 6.98

Price Performance

Historical Comparison
HOV
NGNE

About HOV Hovnanian Enterprises Inc.

Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations. The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments: Northeast, which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia; Southeast, which includes Florida, Georgia, and South Carolina; and West, which includes Arizona, California, and Texas. The firm generates maximum revenue from the West Segment.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: